Kenvue Inc. (KVUE)

FairStock Score: 56/100 — STEADY

Key Financials

Strengths

• Strong free cash flow generation of $1.8B annually provides financial flexibility and potential for shareholder returns
• Diversified portfolio across Self Care, Skin Health, and Essential Health reduces category concentration risk
• Low beta of 0.47 provides defensive characteristics during market volatility
• Established brand portfolio in mature, recurring-revenue categories with predictable demand patterns

Concerns

• Valuation is severely disconnected from intrinsic value with negative margin of safety of -291% and Graham Number of $4.64
• Deteriorating financial quality reflected in Piotroski F-Score of 5/9 and Altman Z-Score of 1.48 approaching distress levels
• Extremely high EV/EBITDA multiple of 62.94 suggests the market is pricing in growth that the fundamentals don't support
• Anemic ROCE of 6.61% indicates the business is barely creating value, destroying shareholder capital in real terms

AI Analysis

Kenvue presents a classic value trap masquerading as a defensive consumer staple. The company operates in attractive markets—over-the-counter medicines and personal care—with recognizable brands and steady cash generation of $1.8B annually. However, the financial metrics tell a troubling story. At a P/E of 22.89 with a Graham Number of merely $4.64, we're paying nearly four times what Graham's conservative framework suggests is prudent. The margin of safety is dangerously negative at -291%, meaning the stock would need to collapse 75% just to reach fair value. The Piotroski F-Score of 5/9 indicates deteriorating financial quality, while the Altman Z-Score of 1.48 suggests distress zone proximity. Most alarming is the EV/EBITDA multiple of 62.94—extraordinarily expensive for a mature, low-growth business. The 6.61% ROCE barely exceeds the cost of capital, indicating value destruction. With 14.39% ROE supported by modest leverage (0.81 D/E), the company generates adequate but uninspiring returns. The latest quarter's 8.73% margin shows operational efficiency, yet revenue growth remains opaque. This is a company paying for yesterday's premium brands in a world fragmenting toward private label and digital health disruption. I'd wait for a 50%+ decline or superior competitive evidence before considering this a Graham-worthy purchase.

Bull Case

Kenvue's defensive consumer staple positioning and $1.8B annual free cash flow provide a durable income base that should support dividend resumption and buybacks, particularly if private label pressures ease. If management successfully executes digital health and telemedicine integration, the company could unlock adjacent revenue streams and justify current valuations.

Bear Case

The company faces structural headwinds from private label competition, e-commerce disruption, and healthcare digitalization while trading at valuation multiples befitting growth companies. If consumer health spending deteriorates or the company fails to maintain margins, the stock could re-rate downward sharply, making current valuations untenable.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer